Antimicrobial activity and spectrum of SCH27899 (ziracin®) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control
- 1 June 1999
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 34 (2) , 103-110
- https://doi.org/10.1016/s0732-8893(98)00093-5
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Association Between Decreased Susceptibility to a New Antibiotic for Treatment of Human Diseases, Everninomicin (SCH 27899), and Resistance to an Antibiotic Used for Growth Promotion in Animals, AvilamycinMicrobial Drug Resistance, 1998
- Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibilityJournal of Antimicrobial Chemotherapy, 1997
- Comparative in-vitro activity of SCH 27899, a novel eveminomicin, and vancomycinJournal of Antimicrobial Chemotherapy, 1996
- Preliminary interpretive criteria for disk diffusion susceptibility testing of SCH 27899, a compound in the everninomicin class of antimicrobial agentsDiagnostic Microbiology and Infectious Disease, 1995
- Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive SpectrumClinical Microbiology & Infection, 1995
- Chemical modification of everninomicins.The Journal of Antibiotics, 1982
- Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative studyJournal of Clinical Microbiology, 1981
- Microbiological Characterization of Everninomicins B and DAntimicrobial Agents and Chemotherapy, 1974